InfaCare Pharmaceutical Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $425M

InfaCare Pharmaceutical General Information

Description

Developer of a pharmaceutical drug intended for the treatment of neonatal and pediatric diseases. The company's pharmaceutical drug includes heme oxygenase inhibitor which is injected via a single, intramuscular injection in the body of term and pre-term newborns facing neonatal HB, breaks down heme and inhibits the body's production of bilirubin for a period of days, enabling clinicians to reduce the need for phototherapy and exchange transfusions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 8 Neshaminy Interplex Drive
  • Suite 221
  • Trevose, PA 19053
  • United States
Primary Industry
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 8 Neshaminy Interplex Drive
  • Suite 221
  • Trevose, PA 19053
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InfaCare Pharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 25-Sep-2017 $425M Completed Generating Revenue
8. Later Stage VC 07-Jun-2017 Completed Clinical Trials - General
7. Later Stage VC (Series C) 08-Jul-2015 Completed Clinical Trials - General
6. Later Stage VC (Series C) 20-Mar-2013 Completed Clinical Trials - General
5. Later Stage VC (Series B) 27-Oct-2008 Completed Startup
4. Early Stage VC (Series A) 10-Mar-2006 Completed Startup
3. Angel (individual) 29-Dec-2003 Completed Startup
2. Angel (individual) 16-Jun-2003 $786K $861K Completed Startup
1. Angel (individual) 06-May-2002 $75K $75K Completed Startup
To view InfaCare Pharmaceutical’s complete valuation and funding history, request access »

InfaCare Pharmaceutical Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Junior Preferred
To view InfaCare Pharmaceutical’s complete cap table history, request access »

InfaCare Pharmaceutical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a pharmaceutical drug intended for the treatment of neonatal and pediatric diseases. The company's pharmace
Other Pharmaceuticals and Biotechnology
Trevose, PA
10 As of 2014

King of Prussia, PA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InfaCare Pharmaceutical Competitors (29)

One of InfaCare Pharmaceutical’s 29 competitors is XyloCor Therapeutics, a Venture Capital-Backed company based in King of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
XyloCor Therapeutics Venture Capital-Backed King of Prussia, PA
Neurelis Venture Capital-Backed San Diego, CA
Voyager Therapeutics Formerly VC-backed Lexington, MA
Pacira BioSciences Formerly VC-backed Tampa, FL
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
You’re viewing 5 of 29 competitors. Get the full list »

InfaCare Pharmaceutical Patents

InfaCare Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017263628-A1 Methods for treating hyperbilirubinemia with stannsoporfin and phototherapy Inactive 12-May-2016
WO-2017197249-A3 Methods for treating hyperbilirubinemia with stannsoporfin and phototherapy Inactive 12-May-2016
WO-2017197249-A2 Methods for treating hyperbilirubinemia with stannsoporfin and phototherapycross-reference to related applications Inactive 12-May-2016
JP-2019052176-A Drug for treatment of infant hyperbilirubinemia or symptoms thereof containing stannsoporfin Pending 01-Dec-2011
JP-2018012717-A Drugs comprising stannsoporfin for treating hyperbilirubinemia Pending 01-Dec-2011 A61K31/555
To view InfaCare Pharmaceutical’s complete patent history, request access »

InfaCare Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InfaCare Pharmaceutical Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlas Venture Venture Capital Minority
HealthCare Ventures Venture Capital Minority
Longitude Capital Venture Capital Minority
Lookout Capital Venture Capital Minority
Pequot Ventures Venture Capital Minority
To view InfaCare Pharmaceutical’s complete investors history, request access »

InfaCare Pharmaceutical FAQs

  • When was InfaCare Pharmaceutical founded?

    InfaCare Pharmaceutical was founded in 2001.

  • Where is InfaCare Pharmaceutical headquartered?

    InfaCare Pharmaceutical is headquartered in Trevose, PA.

  • What is the size of InfaCare Pharmaceutical?

    InfaCare Pharmaceutical has 10 total employees.

  • What industry is InfaCare Pharmaceutical in?

    InfaCare Pharmaceutical’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is InfaCare Pharmaceutical a private or public company?

    InfaCare Pharmaceutical is a Private company.

  • What is the current valuation of InfaCare Pharmaceutical?

    The current valuation of InfaCare Pharmaceutical is .

  • What is InfaCare Pharmaceutical’s current revenue?

    The current revenue for InfaCare Pharmaceutical is .

  • How much funding has InfaCare Pharmaceutical raised over time?

    InfaCare Pharmaceutical has raised $84.1M.

  • Who are InfaCare Pharmaceutical’s investors?

    Atlas Venture, HealthCare Ventures, Longitude Capital, Lookout Capital, and Pequot Ventures have invested in InfaCare Pharmaceutical.

  • Who are InfaCare Pharmaceutical’s competitors?

    XyloCor Therapeutics, Neurelis, Voyager Therapeutics, Pacira BioSciences, and Vertex Pharmaceuticals are some of the 29 competitors of InfaCare Pharmaceutical.

  • When was InfaCare Pharmaceutical acquired?

    InfaCare Pharmaceutical was acquired on 25-Sep-2017.

  • Who acquired InfaCare Pharmaceutical?

    InfaCare Pharmaceutical was acquired by Mallinckrodt Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process